Rates of clinical remission and clinical response were 32.0% and 42.7%, respectively, in Crohn's disease patients receiving therapy with both corticosteroids and anti-tumor necrosis factor (TNF) agents and 35.5% and 46.8% in those receiving only anti
Active choice interventions in an EHR prompted an increase in ordering of cancer screenings but not patient follow-through, while physicians who themselves underwent colorectal cancer (CRC) screening had more patients do so as well.
Clarithromycin triple therapy should be used for first-line treatment of Helicobacter pylori infection only in patients with no history of macrolide exposure who live in areas where H. pylori resistance to clarithromycin is known to be low, among
Three propensity-matched cohorts of patients with nonvalvular atrial fibrillation who had incident exposure to dabigatran, rivaroxaban, or apixaban were compared.
Oral sulfasalazine, diazo-bonded 5-aminosalicylates (5-ASAs), mesalazine, controlled ileal-release budesonide, and budesonide multimatrix, alone or in combination with rectal 5-ASA therapy, were assessed for comparative efficacy and tolerability.
The drug was evaluated in three multicenter, phase 3, randomized, double-blind, placebo-controlled trials involving patients with moderately to severely active disease.
An analysis of U.S. veterans with and without cirrhosis who were tested for SARS-CoV-2 this spring found a 30-day mortality rate of 17.1% in patients with both conditions, compared to 2.3% in those with neither COVID-19 nor cirrhosis.
The Advisory Committee on Immunization Practices (ACIP) changed its recommendations regarding vaccination of patients with chronic liver disease, pregnant women, and those treated with blood products for clotting disorders, among other revisions.
Standard reflux management protocol involved initial consultation that emphasized reflux control and proton-pump inhibitor (PPI) adherence, initiation or continuation of PPI therapy as described, medication reconciliation and assessment or
A Korean cohort study did not find any association between use of proton-pump inhibitors (PPIs) and risk of infection with SARS-CoV-2, but current use was associated with higher risk of a composite endpoint that included ICU admission, mechanical